Glaukos 

$184.89
39
+$0.00+0% Friday 20:00
-$2.89-1.56%Friday 23:30After hours

Statistics

Day High
185.3
Day Low
184.71
52W High
191.62
52W Low
73.16
Volume
21,217
Avg. Volume
-
Mkt Cap
10.91B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.4
-0.3
-0.2
-0.09
Expected EPS
-0.094864
Actual EPS
N/A

Financials

-36.99%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
507.44MRevenue
-187.69MNet Income

Analyst Ratings

184.10Average Price Target
The highest estimate is 202.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GKOS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Align Technology
ALGN
Mkt Cap11.55B
Align Technology competes in the broader medical devices sector, focusing on dental products but shares market space in medical technology advancements.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its medical devices segment, competes in various areas including surgical technologies which can overlap with Glaukos' market.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie, while primarily known for pharmaceuticals, has interests in eye care through its acquisition of Allergan, making it a competitor in the ophthalmology space.
Novartis
NVS
Mkt Cap301.95B
Novartis competes directly in the eye care market through its Alcon division, offering products and solutions in eye health that rival Glaukos' offerings.
Staar Surgical
STAA
Mkt Cap1.16B
STAAR Surgical specializes in ophthalmic products, directly competing with Glaukos in the market for surgical eye care solutions.
Bausch Health Companies
BHC
Mkt Cap2.41B
Bausch Health Companies, through its eye health division, competes in the same ophthalmology and eye care markets as Glaukos.
Cooper Companies
COO
Mkt Cap14.87B
The Cooper Companies operate in the medical device sector focusing on contact lens and women's health, but its eye care division competes with Glaukos in providing medical devices for eye conditions.
Integra Lifesciences
IART
Mkt Cap1.43B
Integra LifeSciences, a provider of medical devices for surgery, competes indirectly with Glaukos through its offerings in surgical instruments and regenerative technologies.

About

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Show more...
CEO
Thomas William Burns
Employees
1094
Country
United States
ISIN
US3773221029
WKN
000A14VCK

Listings

0 Comments

Share your thoughts

FAQ

What is Glaukos stock price today?
The current price of GKOS is $184.89 USD — it has increased by +0% in the past 24 hours. Watch Glaukos stock price performance more closely on the chart.
What is Glaukos stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Glaukos stocks are traded under the ticker GKOS.
Is Glaukos stock price growing?
GKOS stock has fallen by -0.39% compared to the previous week, the month change is a +20.39% rise, over the last year Glaukos has showed a +96.38% increase.
What is Glaukos market cap?
Today Glaukos has the market capitalization of 10.91B
When is the next Glaukos earnings date?
Glaukos is going to release the next earnings report on November 04, 2026.
What were Glaukos earnings last quarter?
GKOS earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.21 USD resulting in a +33.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Glaukos revenue for the last year?
Glaukos revenue for the last year amounts to 507.44M USD.
What is Glaukos net income for the last year?
GKOS net income for the last year is -187.69M USD.
How many employees does Glaukos have?
As of August 24, 2026, the company has 1,094 employees.
In which sector is Glaukos located?
Glaukos operates in the Health & Wellness sector.
When did Glaukos complete a stock split?
Glaukos has not had any recent stock splits.
Where is Glaukos headquartered?
Glaukos is headquartered in ALISO VIEJO, United States.